Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Interventions

Carboplatin 11 pembrolizumab 10 Gemcitabine 8 Cisplatin 8 Rituximab 7 osimertinib 5 durvalumab 5 Specimen Handling 5 Pemetrexed 5 Nivolumab 5 Dexamethasone 5 belzutifan 4 atezolizumab 4 amivantamab 4 Prednisone 4 Paclitaxel 4 Cyclophosphamide 4 Bortezomib 4 trastuzumab deruxtecan 3 olaparib 3 lazertinib 3 entrectinib 3 enfortumab vedotin 3 daratumumab 3 alectinib 3 acalabrutinib 3 X-Rays 3 Vinorelbine 3 Oxaliplatin 3 Midazolam 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × talazoparib × 90 days × Clear all

NCT03395197 2026-04-22

TALAPRO-2

Pfizer

Phase 3 Active not recruiting

1,054 enrolled 21 charts 1 FDA

mCRPC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡